Table 3. Multivariate analysis of clinicopathological traits and CNA events (validated in the replication panel) for the prediction of clinical outcomes.
| Clinical outcome | Predictor | Hazard ratio | P value |
|---|---|---|---|
| Second primary tumors | SMAD4 deletion | 1.81 | 0.016 |
| Second primary tumors | STK11 amplification | 2.09 | 0.041 |
| Second primary tumors | TP53 deletion | 1.72 | 0.025 |
| Second primary tumors | ATM amplification | 1.72 | 0.041 |
| Second primary tumors | pN2c | 2.08 | 0.05 |
| Local recurrence | Pathological tumor stage | 1.4 | 0.011 |
| Local recurrence | RB1 | 1.52 | 0.049 |
| Local recurrence | FGFR1 amplification | 2.12 | 0.011 |
| Local recurrence | PIK3CA amplification | 2.63 | 0.007 |
| Neck control | Pathological stage | 2.26 | 0.009 |
| Distant metastases | Extracapsular spread | 3.39 | 0.000013 |
| Distant metastases | Pathological tumor stage | 1.41 | 0.005 |
| Distant metastases | FGFR1 amplification | 2.28 | 0.006 |
| Disease-free survival | Extracapsular spread | 1.8 | 0.0004 |
| Disease-free survival | Pathological tumor stage | 1.36 | 0.0002 |
| Disease-free survival | PIK3CA amplification | 2.29 | 0.025 |
| Disease-specific survival | Extracapsular spread | 2.14 | 0.00005 |
| Disease-specific survival | Pathological tumor stage | 2.93 | 0.0003 |
| Disease-specific survival | PIK3CA amplification | 2.26 | 0.019 |
| Overall survival | Extracapsular spread | 1.74 | 0.0002 |
| Overall survival | Pathological tumor stage | 1.38 | 0.00005 |
| Overall survival | PIK3CA amplification | 2.12 | 0.002 |
1 Outcomes independently predicted by validated CNA are marked in bold.